A Phase 1/2 clinical trial of AMI-918 in Liver disorders
Latest Information Update: 29 Jun 2022
At a glance
- Drugs AMI-918 (Primary)
- Indications Liver disorders
- Focus Adverse reactions
- 27 Jun 2022 According to an Ambys Medicines media release, company announced the formation of its clinical and scientific advisory boards, the board provides critical input on clinical trial design and patient selection.
- 21 Dec 2021 According to an Ambys Medicines media release, this study is expected to begin in Q2 of 2023.
- 05 Oct 2021 New trial record